Skip to main content
Journal cover image

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.

Publication ,  Journal Article
Dale, DC; Crawford, J; Klippel, Z; Reiner, M; Osslund, T; Fan, E; Morrow, PK; Allcott, K; Lyman, GH
Published in: Support Care Cancer
January 2018

PURPOSE: Filgrastim (NEUPOGEN®) is the originator recombinant human granulocyte colony-stimulating factor widely used for preventing neutropenia-related infections and mobilizing hematopoietic stem cells. This report presents findings of a systematic literature review and meta-analysis of efficacy and safety of originator filgrastim to update previous reports. METHODS: A literature search of electronic databases, congress abstracts, and bibliographies of recent reviews was conducted to identify English-language reports of clinical trials and observational studies evaluating filgrastim in its US-approved indications up to February 2015. Two independent reviewers assessed titles/abstracts and full texts of publications, and extracted data from studies that compared originator filgrastim vs placebo or no treatment. For outcomes with sufficient homogeneous data reported across studies, meta-analysis was performed and relative risk (RR) determined. Data were summarized descriptively for all other evaluated outcomes. RESULTS: A total of 1194 unique articles evaluating originator filgrastim were identified, with 25 meeting eligibility criteria for data extraction: 18 randomized controlled trials, 2 nonrandomized clinical trials, and 5 observational studies. In chemotherapy-induced neutropenia (CIN), filgrastim vs placebo or no treatment significantly reduced febrile neutropenia incidence (RR 0.63, 95% CI 0.53-0.75) and grade 3 or 4 neutropenia incidence (RR 0.50, 95% CI 0.37-0.68). The most commonly reported adverse event (AE) with filgrastim was bone pain (RR 2.61, 95% CI 1.29-5.27 in CIN). Additional efficacy and safety outcomes are described within indications. CONCLUSIONS: This systematic literature review and meta-analysis confirms and updates previous reports on the efficacy and safety of originator filgrastim. Bone pain was the commonly reported AE associated with filgrastim use.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Support Care Cancer

DOI

EISSN

1433-7339

Publication Date

January 2018

Volume

26

Issue

1

Start / End Page

7 / 20

Location

Germany

Related Subject Headings

  • Oncology & Carcinogenesis
  • Humans
  • Hematologic Agents
  • Granulocyte Colony-Stimulating Factor
  • Filgrastim
  • 52 Psychology
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 17 Psychology and Cognitive Sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dale, D. C., Crawford, J., Klippel, Z., Reiner, M., Osslund, T., Fan, E., … Lyman, G. H. (2018). A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer, 26(1), 7–20. https://doi.org/10.1007/s00520-017-3854-x
Dale, David C., Jeffrey Crawford, Zandra Klippel, Maureen Reiner, Timothy Osslund, Ellen Fan, Phuong Khanh Morrow, Kim Allcott, and Gary H. Lyman. “A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.Support Care Cancer 26, no. 1 (January 2018): 7–20. https://doi.org/10.1007/s00520-017-3854-x.
Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer. 2018 Jan;26(1):7–20.
Dale, David C., et al. “A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.Support Care Cancer, vol. 26, no. 1, Jan. 2018, pp. 7–20. Pubmed, doi:10.1007/s00520-017-3854-x.
Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, Morrow PK, Allcott K, Lyman GH. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer. 2018 Jan;26(1):7–20.
Journal cover image

Published In

Support Care Cancer

DOI

EISSN

1433-7339

Publication Date

January 2018

Volume

26

Issue

1

Start / End Page

7 / 20

Location

Germany

Related Subject Headings

  • Oncology & Carcinogenesis
  • Humans
  • Hematologic Agents
  • Granulocyte Colony-Stimulating Factor
  • Filgrastim
  • 52 Psychology
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 17 Psychology and Cognitive Sciences
  • 11 Medical and Health Sciences